ASX - By Stock
|
ATX |
Re:
Ann: Sixth Confirmed Response in Pancreatic Cancer Trial
|
|
ma420
|
60 |
14K |
0 |
23/09/24 |
23/09/24 |
ASX - By Stock
|
60
|
14K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Sixth Confirmed Response in Pancreatic Cancer Trial
|
|
ma420
|
60 |
14K |
0 |
23/09/24 |
23/09/24 |
ASX - By Stock
|
60
|
14K
|
0
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
958 |
339K |
12 |
23/09/24 |
23/09/24 |
ASX - By Stock
|
958
|
339K
|
12
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Sixth Confirmed Response in Pancreatic Cancer Trial
|
|
ma420
|
60 |
14K |
0 |
23/09/24 |
23/09/24 |
ASX - By Stock
|
60
|
14K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Sixth Confirmed Response in Pancreatic Cancer Trial
|
|
ma420
|
60 |
14K |
7 |
23/09/24 |
23/09/24 |
ASX - By Stock
|
60
|
14K
|
7
|
|
ASX - By Stock
|
BDX |
Re:
Ann: BCAL Receives Firm Commitments to Raise $10.5 Million
|
|
ma420
|
79 |
23K |
1 |
22/09/24 |
22/09/24 |
ASX - By Stock
|
79
|
23K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - Media and Industry News
|
|
ma420
|
568 |
232K |
19 |
22/09/24 |
22/09/24 |
ASX - By Stock
|
568
|
232K
|
19
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
ma420
|
22K |
7.8M |
3 |
20/09/24 |
20/09/24 |
ASX - By Stock
|
22K
|
7.8M
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
958 |
339K |
5 |
20/09/24 |
20/09/24 |
ASX - By Stock
|
958
|
339K
|
5
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
958 |
339K |
2 |
20/09/24 |
20/09/24 |
ASX - By Stock
|
958
|
339K
|
2
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ma420
|
11K |
4.0M |
24 |
20/09/24 |
20/09/24 |
General
|
11K
|
4.0M
|
24
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
ma420
|
11K |
4.0M |
3 |
20/09/24 |
20/09/24 |
General
|
11K
|
4.0M
|
3
|
|
ASX - By Stock
|
ATX |
Re:
Ann: FDA Fast Track Designation for Narmafotinib
|
|
ma420
|
26 |
6.8K |
0 |
20/09/24 |
20/09/24 |
ASX - By Stock
|
26
|
6.8K
|
0
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
958 |
339K |
4 |
20/09/24 |
20/09/24 |
ASX - By Stock
|
958
|
339K
|
4
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
ma420
|
22K |
7.8M |
6 |
20/09/24 |
20/09/24 |
ASX - By Stock
|
22K
|
7.8M
|
6
|
|
ASX - By Stock
|
ATX |
Re:
Ann: FDA Fast Track Designation for Narmafotinib
|
|
ma420
|
26 |
6.8K |
3 |
20/09/24 |
20/09/24 |
ASX - By Stock
|
26
|
6.8K
|
3
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - General discussion
|
|
ma420
|
483 |
174K |
7 |
20/09/24 |
20/09/24 |
ASX - By Stock
|
483
|
174K
|
7
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
ma420
|
22K |
7.8M |
7 |
20/09/24 |
20/09/24 |
ASX - By Stock
|
22K
|
7.8M
|
7
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - ASX Charts
|
|
ma420
|
958 |
339K |
13 |
20/09/24 |
20/09/24 |
ASX - By Stock
|
958
|
339K
|
13
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Becoming a substantial holder
|
|
ma420
|
42 |
11K |
1 |
20/09/24 |
20/09/24 |
ASX - By Stock
|
42
|
11K
|
1
|
|
ASX - By Stock
|
ATX |
Re:
Ann: FDA Fast Track Designation for Narmafotinib
|
|
ma420
|
26 |
6.8K |
0 |
20/09/24 |
20/09/24 |
ASX - By Stock
|
26
|
6.8K
|
0
|
|
ASX - By Stock
|
ATX |
Re:
Ann: FDA Fast Track Designation for Narmafotinib
|
|
ma420
|
26 |
6.8K |
0 |
20/09/24 |
20/09/24 |
ASX - By Stock
|
26
|
6.8K
|
0
|
|
ASX - By Stock
|
SNT |
Re:
SNT - Media thread
|
|
ma420
|
14 |
5.6K |
8 |
20/09/24 |
20/09/24 |
ASX - By Stock
|
14
|
5.6K
|
8
|
|
ASX - By Stock
|
ATX |
Re:
Ann: FDA Fast Track Designation for Narmafotinib
|
|
ma420
|
26 |
6.8K |
3 |
20/09/24 |
20/09/24 |
ASX - By Stock
|
26
|
6.8K
|
3
|
|
ASX - By Stock
|
ATX |
Re:
Ann: FDA Fast Track Designation for Narmafotinib
|
|
ma420
|
26 |
6.8K |
5 |
20/09/24 |
20/09/24 |
ASX - By Stock
|
26
|
6.8K
|
5
|
|
ASX - By Stock
|
ATX |
Re:
Ann: FDA Fast Track Designation for Narmafotinib
|
|
ma420
|
26 |
6.8K |
5 |
20/09/24 |
20/09/24 |
ASX - By Stock
|
26
|
6.8K
|
5
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Becoming a substantial holder
|
|
ma420
|
42 |
11K |
2 |
20/09/24 |
20/09/24 |
ASX - By Stock
|
42
|
11K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Shareholder briefing - presentation
|
|
ma420
|
65 |
17K |
9 |
19/09/24 |
19/09/24 |
ASX - By Stock
|
65
|
17K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: EMA pre-submission meeting paves the way for OMPD Request
|
|
ma420
|
16 |
5.7K |
15 |
19/09/24 |
19/09/24 |
ASX - By Stock
|
16
|
5.7K
|
15
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
ma420
|
22K |
7.8M |
7 |
19/09/24 |
19/09/24 |
ASX - By Stock
|
22K
|
7.8M
|
7
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Shareholder briefing - presentation
|
|
ma420
|
65 |
17K |
14 |
19/09/24 |
19/09/24 |
ASX - By Stock
|
65
|
17K
|
14
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Shareholder briefing - presentation
|
|
ma420
|
65 |
17K |
4 |
19/09/24 |
19/09/24 |
ASX - By Stock
|
65
|
17K
|
4
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Shareholder briefing - presentation
|
|
ma420
|
65 |
17K |
5 |
19/09/24 |
19/09/24 |
ASX - By Stock
|
65
|
17K
|
5
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Shareholder briefing - presentation
|
|
ma420
|
65 |
17K |
28 |
18/09/24 |
18/09/24 |
ASX - By Stock
|
65
|
17K
|
28
|
|
ASX - By Stock
|
RAC |
Re:
Ann: HealthInvest 2024 Investor Presentation
|
|
ma420
|
31 |
9.6K |
4 |
18/09/24 |
18/09/24 |
ASX - By Stock
|
31
|
9.6K
|
4
|
|
ASX - By Stock
|
RAC |
Re:
Ann: HealthInvest 2024 Investor Presentation
|
|
ma420
|
31 |
9.6K |
37 |
18/09/24 |
18/09/24 |
ASX - By Stock
|
31
|
9.6K
|
37
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Shareholder briefing - presentation
|
|
ma420
|
65 |
17K |
6 |
18/09/24 |
18/09/24 |
ASX - By Stock
|
65
|
17K
|
6
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Shareholder briefing - presentation
|
|
ma420
|
65 |
17K |
25 |
18/09/24 |
18/09/24 |
ASX - By Stock
|
65
|
17K
|
25
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Shareholder briefing - presentation
|
|
ma420
|
65 |
17K |
15 |
18/09/24 |
18/09/24 |
ASX - By Stock
|
65
|
17K
|
15
|
|
ASX - By Stock
|
RAC |
Re:
Ann: HealthInvest 2024 Investor Presentation
|
|
ma420
|
31 |
9.6K |
34 |
18/09/24 |
18/09/24 |
ASX - By Stock
|
31
|
9.6K
|
34
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Shareholder briefing - presentation
|
|
ma420
|
65 |
17K |
2 |
18/09/24 |
18/09/24 |
ASX - By Stock
|
65
|
17K
|
2
|
|
ASX - By Stock
|
ATX |
Re:
ATX - Industry news
|
|
ma420
|
5 |
2.0K |
5 |
18/09/24 |
18/09/24 |
ASX - By Stock
|
5
|
2.0K
|
5
|
|
ASX - By Stock
|
ATX |
Re:
ATX - Industry news
|
|
ma420
|
5 |
2.0K |
5 |
17/09/24 |
17/09/24 |
ASX - By Stock
|
5
|
2.0K
|
5
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - General discussion
|
|
ma420
|
483 |
174K |
1 |
17/09/24 |
17/09/24 |
ASX - By Stock
|
483
|
174K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - General discussion
|
|
ma420
|
483 |
174K |
9 |
17/09/24 |
17/09/24 |
ASX - By Stock
|
483
|
174K
|
9
|
|
ASX - By Stock
|
SNT |
Re:
Syntara the science explained
|
|
ma420
|
81 |
29K |
1 |
17/09/24 |
17/09/24 |
ASX - By Stock
|
81
|
29K
|
1
|
|
ASX - By Stock
|
SNT |
Re:
Syntara the science explained
|
|
ma420
|
81 |
29K |
1 |
16/09/24 |
16/09/24 |
ASX - By Stock
|
81
|
29K
|
1
|
|
ASX - By Stock
|
SNT |
Re:
Syntara the science explained
|
|
ma420
|
81 |
29K |
1 |
16/09/24 |
16/09/24 |
ASX - By Stock
|
81
|
29K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - General discussion
|
|
ma420
|
483 |
174K |
1 |
16/09/24 |
16/09/24 |
ASX - By Stock
|
483
|
174K
|
1
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - General discussion
|
|
ma420
|
483 |
174K |
2 |
16/09/24 |
16/09/24 |
ASX - By Stock
|
483
|
174K
|
2
|
|